Articles related to CLINICAL STUDY

In a study population of nearly 3.25 million adults receiving COVID boosters from November 2021 through February 2022, the 20-week risk per 1,000 for contracting COVID was 164.2 for the Pfizer-BioNTech vaccine and 159.9 for the Moderna vaccine.

Drawing from animal evidence that aging and metabolic dysfunction result in depletion of NAD+ within neurons, B3 supplementation of 500mg BID for 6 weeks was studied as a means of increasing available NAD+. As published in Nature, a small but significant increase in NAD+ available to neurons was seen with B3 supplementation.

Two-hundred sixteen (216) people with mild-to-moderate disease were treated with 100 mg simufilam tablets twice daily for 12 months. ADAS-Cog-11 score showed a “highly desirable” overall minimal decline in cognitive ability after one year. Simufilam is an oral small molecule designed to to prevent beta and tau amyloid clumping by correctong an altered form of filamin A.

A faulty control arm makes a new trial for tricuspid valve regurgitation intervention seem positive. But in reality, the results probably aren’t.

Thirty-three studies comprised of 2,384 participants in various populations, including community dwellers, nursing home residents, and those with chronic disease, were identified. Hatha yoga was the foundation of most yoga styles, and Iyengar or chair-based methods were frequently used. Measures of gait speed, handgrip strength, balance, lower-extremity strength and endurance, and multicomponent physical performance were used as single-item frailty markers; no studies included a validated definition of frailty.

This study analyzed 147 patients with hormone receptor-positive and HER2-positive metastatic breast cancer (HR+/HER2+ MBC) who received first-line chemotherapy and dual anti-HER2 therapy using a real-world registry dataset. The efficacy of adding endocrine therapy to dual anti-HER2 therapy after chemotherapy discontinuation was studied retrospectively. The researchers discovered that endocrine therapy resulted in statistically significant and clinically meaningful improvements in both PFS and overall survival outcomes. In the first-line treatment of HR+/HER2+ MBC, the current standard practice is to administer a CLEOPATRA trial-based regimen that includes taxane, pertuzumab, and trastuzumab until the best response is achieved and then discontinue chemotherapy. These findings, with a hazard ratio of 0.52 for overall survival with the addition of endocrine therapy, confirm that all patients with HR+/HER2+ MBC should receive endocrine therapy after achieving the best response with chemotherapy.